Objective
To summarize current research status of sperm protein 17 (SP17) in breast cancer.
Method
Bysearching PubMed, Web of Science, CNKI, and Wanfang databases, the studies about expression and function of SP17 in the breast cancer were summarized.
Results
SP17 only expressed in the breast cancer tissue but not in the normal breast tissue. The result of the study showed that SP17 was only detected in the metastatic stage of tumor cells. The preclinical trails found that the breast cancer cells with SP17 positive expression could be killed by the specific T lymphocyte.
Conclusions
SP17 might be a potential target of immunotherapy of breast cancer, it might promote metastasis of cancer. More studies are needed to further explore its function in tumor development, thus accelerate its application in clinical practice.
ObjectiveTo systematically review the efficacy and safety of CoQ10 for idiopathic oligoasthenoteratozoospermia (iOAT).
MethodsWe searched databases including PubMed, EMbase, MEDLINE, The Cochrane Library, CBM, CNKI, VIP and WanFang Data from inception to May 31th 2016 for randomized controlled trials (RCTs) on CoQ10 in the treatment of iOAT. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software.
ResultsSeven RCTs involving 803 patients were included. The results of meta-analysis showed, compared with the control group, the CoQ10 group could significantly increase sperm concentration (MD=3.37, 95%CI 0.68 to 6.05, P=0.01), the number of A grade spermatozoa (MD=5.06, 95%CI 3.84 to 6.28, P < 0.000 01), the number of A+B grade spermatozoa (MD=7.72, 95%CI 4.19 to 11.26, P < 0.000 1), the rate of morphologically normal sperm (MD=1.89, 95%CI 0.63 to 3.16, P=0.003) and sperm coenzyme Q10 level (MD=40.02, 95%CI 24.73 to 55.31, P < 0.000 01), while not improve the levels of serum sex hormone (FSH: MD=–3.48, 95%CI –5.17 to –1.79, P < 0.000 1; LH: MD=–3.23, 95%CI –7.55 to 1.08, P=0.14; T: MD=0.45, 95%CI –3.31 to 4.20, P=0.82). No significant difference in adverse event was noted between two groups.
ConclusionThe evidence suggests that CoQ10 as empiric medical therapy for iOAT with low non-serious adverse event associated, may improve sperm concentration and percent sperm motility. However, the strength of evidence is low due to high risk of bias of the included studies. More rigorous studies are needed to verify the above conclusion.
